ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings
ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于开展外汇套期保值业务可行性分析报告 | 2025-04-28 | Chinese | |
| 创业板上市公司股权激励计划自查表 | 2025-04-28 | Chinese | |
| 睿智医药2025年限制性股票激励计划（草案） | 2025-04-28 | Chinese | |
| 关于2024年度计提资产减值准备的公告 | 2025-04-28 | Chinese | |
| 2024年年度报告摘要 | 2025-04-28 | Chinese | |
| 2024年度非经营性资金占用及其他关联资金往来情况的专项报告 | 2025-04-28 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 36044192 | 关于开展外汇套期保值业务可行性分析报告 | 2025-04-28 | Chinese | ||
| 36044185 | 创业板上市公司股权激励计划自查表 | 2025-04-28 | Chinese | ||
| 36044177 | 睿智医药2025年限制性股票激励计划（草案） | 2025-04-28 | Chinese | ||
| 36044144 | 关于2024年度计提资产减值准备的公告 | 2025-04-28 | Chinese | ||
| 36044139 | 2024年年度报告摘要 | 2025-04-28 | Chinese | ||
| 36044136 | 2024年度非经营性资金占用及其他关联资金往来情况的专项报告 | 2025-04-28 | Chinese | ||
| 36044126 | 关于会计政策变更的公告 | 2025-04-28 | Chinese | ||
| 36044121 | 独立董事2024年度述职报告（郭志成） | 2025-04-28 | Chinese | ||
| 36044113 | 北京博星证券投资顾问有限公司关于睿智医药科技股份有限公司详式权益变动报告书之财务顾问核查意见 | 2025-04-07 | Chinese | ||
| 36044100 | 2024年度向特定对象发行股票募集资金使用可行性分析报告（修订稿） | 2025-04-01 | Chinese | ||
| 36044093 | 附条件生效的股份认购协议（修订稿） | 2025-04-01 | Chinese | ||
| 36044082 | 2024年度向特定对象发行股票预案（修订稿） | 2025-04-01 | Chinese | ||
| 36044051 | 关于2024年度向特定对象发行股票摊薄即期回报的影响与填补回报措施及相关主体承诺（修订稿）的公告 | 2025-04-01 | Chinese | ||
| 36044036 | 关于与特定对象签署附条件生效的股份认购协议（修订稿）暨关联交易的公告 | 2025-04-01 | Chinese | ||
| 36044024 | 第六届监事会第五次会议决议公告 | 2025-04-01 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ChemPartner PharmaTech Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55161/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55161 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55161 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55161 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55161}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ChemPartner PharmaTech Co., Ltd. (id: 55161)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.